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INVESTIGATE THE ROLE BROMODOMAIN- AND PLANT  
 
HOMEODOMAIN-LINKED ZINC FINGER-CONTAINING PROTEIN 1 (BRPF1) 
 
PLAYS IN MEDULLOBLASTOMA 
 
KELLY DROZDOWICZ  
ABSTRACT 
Background: Medulloblastoma (MB) is the most common malignant brain tumor 
in children, accounting for 15-20% of all pediatric brain tumors. In patients with 
MB, prognosis depends heavily on the molecular makeup of the tumor. New 
genomic approaches over the last decade have enabled researchers to sub-
classify MB based on differences in the transcriptome: WNT, Sonic hedgehog 
(SHH), Group 3 (MYC-amplified), and Group 4 (heterogeneous). SHH tumors 
represent a third of all MB cases, and small-molecule inhibitors have already 
been developed that target SHH signaling. Most notably, vismodegib has shown 
great promise in the treatment of MB and other SHH-driven cancers by targeting 
Smoothened (SMO), an upstream regulator of GLI activity. However, most 
patients who had initially responded to the drug quickly acquired point 
mutations in SMO that led to treatment resistance. In addition, patients who 
harbored mutations downstream of SMO had no response to treatment and 
were found to be intrinsically resistant. Although most patients with SHH-MB 
can be cured, current treatments often require broad base therapies, such as 
radiation and chemotherapy, which can have harmful and long-lasting side 
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effects. These observations underscore the need for less toxic, more targeted 
therapies that act at the level of the GLI family of transcription factors 
themselves. However, as transcription factors are generally considered 
undruggable, Dr. Robbins’ group at the University of Miami Miller School of 
Medicine sought to address this need by using focused screens of siRNAs or 
small molecules that target epigenetic GLI regulators. They identified several 
candidates that act as readers, writers, and/or erasers of protein acetylation and 
methylation and showed that a subset of these candidates act downstream of 
SMO to attenuate GLI signaling (data not yet published). Bromodomain- and 
Plant Homeodomain-linked Zinc Finger-containing Protein 1 (BRPF1) was one of 
these candidates and further analysis revealed that its knockdown reduced Gli1 
expression by more than 50%. Recent studies link BRPF1 to cerebellar 
development and tumor formation in SHH-MB and may be suggestive of its role 
as a negative regulator. 
 
Objectives: We sought to compare basal levels of Brpf1 expression in normal 
versus MB in mice; to characterize Brpf1 knockdown versus overexpression in 
SHH cell lines; and to determine if BRPF1 merits further investigation as a 
candidate for future drug targeting therapies in MB and other SHH-driven 
cancers. 
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Methods: We used RT-qPCR and immunoblotting analysis to look at Brpf1 
expression in Ptch+/- and adult wild-type mice. cDNA and protein samples were 
donated by colleagues in the lab. We also grew and maintained SHH Light2 
cells in culture and then used these cells to carry out siRNA and plasmid DNA 
transfections. RNA extraction, RT-PCR, and RT-qPCR were used to examine 
transfection efficiency and its effect on Gli1 expression. 
 
Results: Brpf1 levels were higher in SHH-MB compared to normal cerebellum. 
However, BRPF1 proteins were not detected in either normal or tumor samples. 
Brpf1 knockdown in Light2 cells correlated with an overall decrease in Gli1 
expression while overexpression had no obvious affect on Gli1 expression. 
 
Conclusions: Our findings suggest that BRPF1 may function as a positive 
regulator of GLI activity. Recent studies verify this claim at least partially stating 
that BRPF1 acts as both a positive and negative regulator of gene expression 
depending on the context. Thus, before we can draw any final conclusions, 
more research is needed to look at BRPF1 in the specific context of the SHH 
pathway and developing cerebellum. 
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INTRODUCTION 
 
Medulloblastoma (MB) is the most common malignant brain tumor in 
children, accounting for 15-20% of all pediatric brain tumors1,2. The American 
Cancer Society estimates that between 250 and 500 children are diagnosed 
with MB each year in the United States3. Adult MB is much less common and 
accounts for only 1% of all adult brain tumors4. MB starts in the cerebellum, the 
part of the brain that controls balance, coordination, and other complex motor 
functions, and can spread to other parts of the brain and spinal cord through the 
cerebrospinal fluid (CSF)4,5,6. These tumors are fast growing and frequently 
compress (or grow into) the fourth ventricle, impeding normal CSF flow and 
causing hydrocephalus5,7,8. As a result, most patients present with symptoms of 
increased intracranial pressure such as headaches and vomiting5,8. The exact 
cause of MB is unknown; however, there are a few rare, genetic syndromes that 
have been linked to increased risk of developing this type of cancer (e.g. Li-
Fraumeni and Gorlin Syndrome)6,9. 
In patients with MB, prognosis depends heavily on the molecular makeup 
of the tumor10,11,12. Traditionally, classification schemes were based primarily on 
histopathology (classic vs. desmoplastic/nodular vs. extensive nodularity vs. 
large-cell/anaplastic)12,13. However, over the last decade, new genomic 
approaches have enabled research groups to sub-classify MB based on 
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differences in the transcriptome: WNT, Sonic hedgehog (SHH), Group 3 (MYC-
amplified), and Group 4 (heterogeneous)12,14. WNT tumors have the best long-
term prognosis, 95% of children and 100% of adults survive past five 
years11,15,16. Group 3 tumors have the worst prognosis, which is likely attributable 
to their tendency to gain and/or lose multiple chromosomes11,15,16. Overall, the 
SHH subgroup is most common in infants and adults, representing a third of all 
MB cases11,17. Furthermore, small-molecule inhibitors have already been 
developed that target SHH tumors17,18. 
 
SHH-MB 
SHH-MB was named after the signaling pathway thought to drive tumor 
formation in that particular subgroup, i.e. the Hedgehog (HH) signaling 
pathway12. During normal cerebellar development, SHH signaling tells the cells 
in the outermost layer of the cerebellum to divide and ultimately dictates the size 
and pattern of the organ11,19. In SHH-MB, this pathway is permanently turned on 
and the cells keep growing and dividing11. SHH tumors frequently possess 
mutations in Patched 1 (PTCH1), Smoothened (SMO), and/or Suppressor of 
Fused (SUFU), all key regulators of the SHH pathway11,17. Additionally, recent 
studies propose that SHH-MB can be further classified into three subtypes 
based on age group: infants (0-3 years), children (3-16 years), and adults (>16 
years)11,20. PTCH1 mutations are found in more or less equal frequencies across 
! !
3 
all age groups11. In contrast, SUFU mutations are found predominantly in 
infants; SMO mutations are found predominantly in adults; and germline TP53 
mutations (i.e. Li-Fraumeni Syndrome) are found most commonly in children11,20. 
These findings suggest that in order for SHH-MB treatments to be effective, 
they should (1) target the SHH pathway and (2) consider the genetics behind 
each tumor. 
 
SHH Pathway 
HH proteins are powerful signaling molecules that can act as 
morphogens, mitogens, or survival factors depending on the context21,22. In 
vertebrates, there are three principal HH ligands: Sonic hedgehog (SHH), Desert 
hedgehog (DHH), and Indian hedgehog (IHH)22. These are synthesized as 
precursor proteins and then doubly-lipid modified before being secreted from 
the cell22,23. SHH signaling in vertebrates (Figure 1) depends on the primary 
cilium, an antenna-like organelle that extends from the surface of almost every 
cell type22,24. The cilium functions as a signal transduction machine, trafficking 
the HH signaling complex (HSC) up and down microtubules25. 
SHH signaling is activated when the SHH ligand binds to the 12-
transmembrane receptor Patched (PTCH) and coreceptor IHOG (CDO, BOC, or 
GAS1) at the base of the cilium22,26,27. Binding between PTCH and SHH triggers 
the activation and phosphorylation of SMO, a G protein-coupled receptor22,28,29. 
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Active SMO moves to the tip of the cilium and binds to the KIF7-SUFU-GLI 
complex or HSC, causing GLI to dissociate from SUFU and form GLIA, a 
transcriptional activator22,30,31. GLIA translocates to the cytoplasm and then to the 
nucleus, where it promotes expression of SHH target genes (GLI1, PTCH1, 
CYCLIN D, and MYC)22.32. In the absence of SHH, PTCH prevents SMO from 
accumulating in the cilium, and SUFU promotes phosphorylation of GLI by PKA, 
GSK3, and CK122,30,31. These phosphorylation events target GLI for proteasomal 
cleavage, ultimately leading to the formation of GLIR, a transcriptional 
repressor22,30. GLIR then enters the nucleus and binds to a specific region of DNA 
inhibiting transcription of SHH target genes22,32. 
! !
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Figure 1: SHH signaling in vertebrates. GLI proteins are processed into transcriptional 
repressors in the absence of SHH and transcriptional activators in the presence of 
SHH22. This figure was adapted from a review published by Robbins et. al 201222. !!!
Current Treatments 
In treating MB, the first step is almost always surgery, the goal being to 
take out as much of the tumor as possible5,6. This is usually followed by radiation 
to the brain and spinal cord and then several months of chemotherapy5,6. The 
use of radiation in young children is controversial, and some physicians choose 
to treat the tumor in another way or restrict radiation to only one part of the 
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brain6. Other new and exciting treatment options target the SHH pathway 
directly, mainly by way of SMO17,18. 
Cyclopamine, a naturally occurring chemical, was first identified as a 
teratogen after causing birth defects in sheep11,33,34. It was later discovered that 
cyclopamine acted as a SMO antagonist, suppressing SHH signaling11,33,34. 
Although it failed to translate clinically, cyclopamine sparked the idea of using 
SHH pathway inhibitors in cancer11,35. Today, several types of SMO antagonists 
are being evaluated, the most advanced being vismodegib11,36. Vismodegib 
recently received FDA approval for advanced basal cell carcinoma (BCC) 
patients, and clinical trials are already underway for SHH-MB patients11,37,38,39. 
Overall survival of patients with SHH-MB is about 70%, but current treatments 
often involve lifelong side effects and recurrent tumors are all but resistant to 
treatment4,11,40,41. 
 
Side Effects and Drug Resistance 
While most patients with MB can be cured, the cost in terms of long-term 
side effects can be very high. Younger patients are especially vulnerable to 
radiation and can develop learning disabilities and/or fertility problems as a 
result of exposure6,40,41. In addition, both radiation and chemotherapy have been 
shown to increase the risk of developing secondary cancers or malignancies 
later on6,40,41. Physicians are working towards reducing these late effects, either 
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by limiting the amount of radiation or using more targeted drugs with less 
toxicity; still radiotherapy/chemotherapy may be a patient’s best or only 
option4,6. 
Secondly, although the use of SMO antagonists remains a promising 
avenue for cancer therapy, not everyone responds to treatment11,17. As 
aforementioned, SHH-MB can be split into different subtypes based on age 
group/genetic background11,20. Patients with mutations downstream of SMO, 
such as infants with SUFU mutations, were found to be intrinsically resistant to 
SMO antagonists11,17,20. On the other hand, patients with mutations upstream of 
SMO, such as adults harboring either PTCH1 or SMO mutations, showed the 
best response to treatment11,20. Furthermore, despite positive feedback from 
vismodegib’s early clinical studies, almost all BCC and SHH-MB patients 
relapsed after initially responding to the drug11,42,43. Later studies revealed that 
these patients had quickly acquired point mutations in SMO resulting in 
treatment resistance42,43. 
As effective as current treatments are, combinations of radiation and 
chemotherapy have incredibly harmful and lasting effects, and SHH inhibitors 
fail to address tumors activated downstream of Smo and at best, only 
transiently inhibit tumor growth. These observations underscore the need for 
less toxic, more targeted therapies that act at the level of the GLI family of 
transcription factors themselves44. While transcription factors are generally 
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considered undruggable, epigenetic regulators have emerged as important drug 
targets in a subset of cancers and may suggest new drug targets in SHH-
MB45,46. 
 
Epigenetic Regulators of Gli Expression  
Epigenetics is the science of how cells turn genes on or off47. In the 
nucleus of a cell, DNA wraps around histone proteins to form chromatin48,49. 
When chromatin is active, also known as euchromatin, the associated DNA can 
be transcribed48,49. On the other hand, when chromatin is inactive or condensed 
(i.e. heterochromatin), DNA cannot be transcribed and those genes are 
effectively silenced48,49. Epigenetic modulators thus control which genes are 
expressed or silenced by loosening or tightening the DNA wrapped within 
chromatin45,48,49. They do this in four main ways: 1) adding acetyl or methyl 
groups to histones (writers), 2) removing acetyl or methyl groups from histones 
(erasers), 3) binding these modified histones and then recruiting scaffolding 
proteins (readers), and 4) remodeling nucleosomes (remodelers)45,49. Acetylation 
is usually a marker for active chromatin while deacetylation is generally a marker 
for heterochromatin48. Histone methylation, in contrast, can be associated with 
both active and inactive regions of chromatin48. 
Genetic and epigenetic mechanisms are not separate events in 
cancer50,51. Epigenetic changes can cause genetic mutations (e.g. 
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hypermethylating tumor suppressor genes), and genetic mutations in epigenetic 
regulators can lead to an entirely different epigenome50. Up until a few years 
ago, mutations in genes that control these epigenetic processes were largely 
unknown or overlooked in human cancers50. The discovery that these mutations 
are not only present but also very common in cancer has opened the door to 
further drug development, specifically targeting epigenetic regulators45,47,48,50,51. 
In addition, unlike DNA sequence mutations, epigenetic changes are by nature 
reversible making these regulators an ideal target48,50. 
Dr. Robbins’ group at the University of Miami Miller School of Medicine 
has been working to identify and characterize a novel set of druggable GLI 
regulators. To this end, they used focused screens of siRNAs known to target 
regulators of Gli expression and identified several candidates that act as 
readers, writers, and/or erasers of protein acetylation and methylation (Figure 2). 
They also showed that a subset of these candidates do so by acting 
downstream of SMO (data not yet published). Bromodomain- and Plant 
Homeodomain-linked Zinc Finger-containing Protein 1 (BRPF1) was one of 
these candidates and further analysis revealed that its knockdown reduced Gli1 
expression by more than 50%. Accordingly, this study will focus on the specific 
role BRPF1 plays in SHH-driven cancers, with an emphasis on MB. 
! !
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Acetylation
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Ubiquitination/SUMOlyation 
 
Figure 2: siRNA screen of epigenetic GLI regulators. Dr. Robbins’ group screened 
for epigenetic regulators in Light2 cells, taking advantage of two independently 
regulated luciferase reporter genes. Cells were stimulated with a HH agonist and then 
treated with a 600-member siRNA library that targets various transcriptional processes. 
Candidates were prioritized by reductions of greater than 50% in luciferase activity. Of 
these, 53 candidates were selected, 14 of which were identified as epigenetic 
regulators. The ratio of distinct categories of these prioritized candidates is shown in 
the pie chart above. This data is not yet published. 
 
 
 
BRPF1 
BRPF1 acts as both a reader and co-writer of the epigenetic language52,. 
It is made up of double PHD fingers, a bromodomain, and a PWWP domain. 
These motifs allow BRPF1 to interact with histone H3, acetylated lysine 
residues, and methylated histone H3, respectively52,53,54. In addition, BRPF1 
interacts with and activates three different histone acetyltransferases or HATs: 
monocytic leukemia zinc finger protein (MOZ), MOZ-related factor (MORF), and 
histone acetyltransferase bound to ORC1 (HBO1)52,53,54. BRPF1 serves as a kind 
of scaffold, bringing together MOZ, MORF, and HBO1 with two other subunits 
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to form tetrameric HAT complexes52,55. While BRPF1’s role as a multivalent 
chromatin regulator is well established, researchers are just learning about its 
biological function in mammals52,53,54. 
BRPF1 and its interactions with MOZ and MORF have been linked to 
numerous neurological disorders52,55. The MORF gene itself is mutated in four 
neurodevelopmental disorders56,57,58,59, and in a recent study, Yan et al. 2017 
showed that mutations in Brpf1 cause intellectual disabilities and aberrant H3 
acetylation60. Likewise, in a related study, You et al. 2015 showed that BRPF1 is 
critical for proper forebrain development in mice52. They discovered that 
forebrain-specific inactivation of Brpf1 caused early postnatal lethality, an 
abnormal neocortex, and partial agenesis of the corpus callosum52. They also 
found that BRPF1 functions as both an activator and a silencer of gene 
expression depending on the context52. In addition to the forebrain, BRPF1 is 
highly expressed in the mouse cerebellum, specifically the external germinal 
layer61. Arguably related to this, researchers also found that BRPF1 is frequently 
mutated in adult SHH-MB (Table 1)20, and abnormal expression of MOZ is 
associated with CSF metastases62. Current research portrays an obvious 
relationship between BRPF1 and brain development; however, there is still a lot 
to learn about the specifics of this relationship and how it is affected in cancer.
! ! !
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Table 1: BRPF1 is frequently mutated in adult SHH-MB. Next-generation sequencing of SHH-MB showed that tumors in 
infants, children, and adults are genomically distinct20. BRPF1 was altered in ~20% of adult SHH-MB cases20. This table was 
adapted from data published in Kool et al. 201420 
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Specific Aims 
BRPF1 is a multivalent chromatin regulator that plays a key role in brain 
development and has been linked to tumor formation in SHH-MB52. Multiple 
levels of control regulate the SHH signaling cascade, and many key regulators 
are also tumor suppressors since loss-of-function mutations lead to activation of 
the pathway63. This fact, along with BRPF1’s mutation spectrum in adult SHH-
MB (see Table 1), seems to suggest that it may in fact function as a negative 
regulator of GLI expression. However, while recent studies give a general idea of 
BRPF1’s role in cerebellar development, little is known about what this role 
actually is and how it is changed in cancer52,53,54. As an epigenetic GLI regulator 
that acts downstream of SMO, BRPF1 represents a potential drug target that 
could help to address some of the problems associated with current MB 
treatments. Therefore, the purpose of our thesis is to:   
1. Compare basal levels of Brpf1 expression in normal versus tumor 
cerebellum in mice 
2. Characterize Brpf1 knockdown versus overexpression in SHH cell 
lines 
3. Determine if BRPF1 merits further investigation as a candidate for 
future drug targeting therapies in MB and other SHH-driven cancers 
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METHODS !
Mice Samples 
cDNA and protein samples were donated by colleagues in the lab. Tumor 
samples were collected from Ptch+/- mice, and cerebellar samples were obtained 
from the white matter of adult wild-type mice. 
 
RT-qPCR 
Real time qPCR was performed using the TaqMan® Universal PCR 
Master Mix (Applied Biosystems) and TaqMan® Gene Expression Assays 
(Applied Biosystems) specific for Gapdh, Brpf1, and/or Gli1. Gapdh was used to 
normalize cell data. Gli1 was used as an indicator of SHH activity. Reactions 
were done in 96-well plates and covered with optical adhesive film. Thermal 
cycler conditions were set according to the manufacturer’s instructions: one 
cycle of 95°C for 10 minutes and 40 cycles of 95°C for 15 seconds and 60°C for 
1 minute. Cycle threshold (Ct) values were used to calculate relative gene 
expression. 
 
Immunoblot Analysis 
Protein samples were diluted in a sample loading buffer with β-
mercaptoethanol and heated at 95°C for 5-10 minutes. Equal amounts of protein 
! ! !
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(30 μg/sample) were loaded into a 10% SDS-PAGE gel and run for 45 minutes at 
~100 V and 27 mA. The gel was transferred onto a nitrocellulose membrane 
using a Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad) for 75 
minutes at 20 V and ~300 mA. The membrane was blocked with 5% milk/TBS-T 
(tris-buffered saline with tween) for 1-2 hours at room temperature, and the 
primary antibody (diluted in 5% milk) was added and left to incubate at 4°C 
overnight. The membrane was washed 3 times with 10-20 ml of TBS-T (5 
minutes each wash) and incubated with the secondary antibody (diluted in 1% 
milk) for 1 hour at room temperature. The membrane was washed with TBS-T 
again, transferred to a clear plastic wrap, and covered in Pierce™ ECL Western 
Blotting Substrate (Thermo Scientific). Images were obtained in a darkroom 
using a special cassette and film developer. Note: BRPF1 and GAPDH were 
blotted separately (the membrane cut in half) and then pieced together for 
developing.  
 
Cell Culture 
SHH Light2 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% newborn calf serum (NCS), 0.2 μg/ml 
G418, 0.1 μg/ml Zeocin, and 1% penicillin and streptomycin (P/S). Cells were 
grown at 37°C in the presence of 5% CO2 and were split by trypsinization when 
they reached ~80-90% confluence. 
! ! !
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RNA Extraction 
Total RNA was isolated from Light2 cells with the RNeasy® Mini Kit 
(Qiagen). Concentration was determined using the NanoDrop 1000 
Spectrophotometer (Thermo Scientific). 
 
RT-PCR 
cDNA was synthesized using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Thermocycling conditions were set per 
protocol. 
 
siRNA Transfection 
Light2 cells were plated into 12-well plates at a density of either 50,000 or 
100,000 cells per well. After 24 hours of incubation, cells were transfected with 
siRNAs (100 nM/well) using Lipofectamine® 2000 (Invitrogen) diluted in Opti-
MEM® I Reduced Serum Medium (Invitrogen). Lipid siRNA complexes were 
prepared via a 2-step dilution method as per protocol64. Cells were incubated for 
48 hours following transfection and then treated with either SAG (Smoothened 
Agonist) or DMSO (control) in Eagle’s Basal Medium (BME) containing 0.5% 
NCS and 1% P/S. Cells were incubated for another 24 hours and then lysed. 
Scrambled sequence siRNA was used as the negative control, and Brd4 with its 
! ! !
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siRNA counterpart was used as the positive control. FlexiTube GeneSolution 
(Qiagen) with 4 preselected siRNAs (1, 2, 5, and 7) was used to target Brpf1. 
 
Plasmid DNA Transfection 
Light2 cells were plated into 12-well plates at a density of 20,000, 40,000, 
or 80,000 cells per well. After 24 hours of incubation, cells were transfected with 
GFP-tagged plasmids (1.0 μg/well) using Lipofectamine® 2000 (Invitrogen) 
diluted in Opti-MEM® I Reduced Serum Medium (Invitrogen). Lipid DNA 
complexes were prepared via a 2-step dilution method as mentioned above64. 
Cells were incubated for 48 hours following transfection and then treated with 
either SAG or DMSO in BME containing 0.5% NCS and 1% P/S. Cells were 
incubated for another 24 hours and then lysed. Human GFP-BRPF1 was the 
plasmid of interest, and GFP by itself was used as the positive control. 
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RESULTS 
 
Brpf1 Levels are Higher in Tumor Cerebellum 
RT-qPCR was run to determine Brpf1’s baseline level of expression in 
normal versus tumor cerebellum. As previously stated, cDNA samples from 
Ptch+/- and wild-type mice were donated by colleagues in the lab. There were a 
total of five samples, three normal cerebellum (C) and two SHH-MB (T) samples. 
Both tumor samples showed slightly higher Brpf1 levels (between 1-2 cycles) 
when compared to normal samples (Figure 3). Ct values were normalized to 
Gapdh, and C1 was set as the control (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
Figure 3: Brpf1 levels are higher in SHH-MB compared to normal cerebellum. RT-
qPCR was used to determine Brpf1 expression in normal (C) versus tumor (T) 
cerebellum. All data was normalized to Gapdh, and C1 was used as the control. Error 
bars indicate the SD of duplicate technical repeats.  
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Table 2: Analysis of Brpf1 in normal (C) versus tumor cerebellum (T) using RT-
qPCR. Brpf1 expression was normalized to Gapdh. C1 is marked with an “*” to indicate 
that it was set as the control. 
 
 
 
 
 
 
 
 
BRPF1 Proteins are Not Detected in Normal or Tumor Cerebellum 
Immunoblotting was used to detect basal BRPF1 protein levels in normal 
and tumor cerebellum (Figure 4). Protein lysates from Ptch+/- and wild-type mice 
were donated by colleagues in the lab. There were a total of six samples, three 
normal cerebellum (C) and three SHH-MB (T) samples. In the first blot (Figure 
4A), a faint band was detected at ~150 kDa, which could arguably be a signal 
for BRPF1 (~140 kDa). However, in the second and repeated blots thereafter 
(Figure 4B), no signals or possible signals for BRPF1 were detected in any of the 
samples. Thus, this was likely just artifact and not a true signal for BRPF1. 
GAPDH (~37 kDa) was the only signal consistently detected in all blots and 
samples. 
 
 
Gene Sample Ct (Threshold cycle) Normalization Standard deviation 
Brpf1 C1* 23.37 1 0.05468 
C2 23.62 0.9215 0.09447 
C3 23.46 0.9118 0.08502 
T1 22.1 2.76898 0.18073 
T2 24.01 2.16252 0.23778 
Gapdh C1* 16.83 N/A N/A 
C2 16.92 N/A N/A 
C3 16.78 N/A N/A 
T1 17.03 N/A N/A 
T2 18.58 N/A N/A 
! ! !
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Figure 4: Immunoblotting analysis of BRPF1 in normal (C) versus tumor (T) 
cerebellum. A. The first blot showed a questionable band at ~150 kDa, which was 
likely artifact and not a signal for BRPF1. B. Repeated blots showed no signals for 
BRPF1. GAPDH was reliably detected in all blots and samples. Note: BRPF1 and 
GAPDH were blotted separately (the membrane cut in half) and then pieced together for 
developing. 
 
 
 
Knockdown of Brpf1 in Light2 Cells Results in Decreased Gli1 Expression 
RT-qPCR was used to investigate the effects of Brpf1 knockdown in 
Light2 cells (Figure 5). In the 50,000-cells/well plate (Figure 5A), knockdown 
efficiency ranged from 30-35% for siRNAs 2, 5, and 7 as well as the Brd4 
control. Knockdown was marginally better in the 100,000-cells/well plate (Figure 
5B) with efficiency ranging from 30-40% in siRNAs 2 and 5 and the Brd4 
control. In both plates, siRNA 1 failed to knockdown Brpf1. Most excitingly, 
though, Brpf1 knockdown seemed to correlate with or at least roughly parallel a 
decrease in Gli1 expression. Ct values were normalized to Gapdh, and 
Scrambled (SAG) was set as the control (Tables 3 and 4). 
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Figure 5: Brpf1 knockdown in Light2 cells results in decreased Gli1 expression. A. 
50,000-cells/well plate. B. 100,000-cells/well plate. All data was normalized to Gapdh, 
and Scrambled (SAG) was used as the control. Error bars indicate the SD of duplicate 
technical repeats. 
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Table 3: RT-qPCR analysis of Brpf1 knockdown in Light2 cells (50,000 cells/well 
plate). Gli1 and Brpf1 expression were both normalized to Gapdh. Scrambled (SAG) is 
marked with an “*” to indicate that it was set as the control. 
 
 
 
 
 
Gene Sample Ct (Threshold 
cycle) 
Normalization Standard 
deviation 
Gli1 Scrambled 
(DMSO) 
36.07 0.03493 0.00219 
 Scrambled 
(SAG)* 
31.12 1 0.04871 
 siRNA 1 31.77 1.4639 0.57087 
 siRNA 2 31.73 0.57791 0.03849 
 siRNA 5 32.11 0.51282 0.07421 
 siRNA 7 32.37 0.4093 0.02517 
 Brd4 31.26 0.93011 0.08393 
 Brd4 control 31.7 0.69587 0.06376 
Brpf1 Scrambled 
(DMSO) 
26.65 1.04315 0.0564 
 Scrambled 
(SAG)* 
26.6 1 0.04628 
 siRNA 1 26.54 2.40196 0.91775 
 siRNA 2 27.03 0.65505 0.05097 
 siRNA 5 27.18 0.68475 0.0875 
 siRNA 7 27.17 0.65904 0.03519 
 Brd4 26.63 1.00497 0.04763 
 Brd4 control 26.82 0.89962 0.02533 
Gapdh Scrambled 
(DMSO) 
19.54 N/A N/A 
 Scrambled 
(SAG)* 
19.43 N/A N/A 
 siRNA 1 20.63 N/A N/A 
 siRNA 2 19.25 N/A N/A 
 siRNA 5 19.46 N/A N/A 
 siRNA 7 19.39 N/A N/A 
 Brd4 19.46 N/A N/A 
 Brd4 control 19.49 N/A N/A 
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Table 4: RT-qPCR analysis of Brpf1 knockdown in Light2 cells (100,000 cells/well 
plate). Gli1 and Brpf1 expression were both normalized to Gapdh. Scrambled (SAG) is 
marked with an “*” to indicate that it was set as the control. 
 
 
 
 
 
 
Gene Sample Ct (Threshold 
cycle) 
Normalization Standard 
deviation 
Gli1 Scrambled 
(DMSO) 
36.29 0.02068 0.00179 
 Scrambled 
(SAG)* 
30.66 1 0.04595 
 siRNA 1 30.72 1.02175 0.10416 
 siRNA 2 31.21 0.67669 0.04149 
 siRNA 5 31.44 0.52358 0.02005 
 siRNA 7 31.77 0.54197 0.10894 
 Brd4 30.63 0.93633 0.02366 
 Brd4 control 31.37 0.59172 0.01537 
Brpf1 Scrambled 
(DMSO) 
26.44 1.03606 0.04525 
 Scrambled 
(SAG)* 
26.45 1 0.02278 
 siRNA 1 26.48 1.04872 0.03113 
 siRNA 2 26.98 0.68918 0.04622 
 siRNA 5 26.97 0.62986 0.02207 
 siRNA 7 26.79 0.92539 0.07188 
 Brd4 26.52 0.87667 0.05007 
 Brd4 control 26.48 0.95183 0.08773 
Gapdh Scrambled 
(DMSO) 
18.61 N/A N/A 
 Scrambled 
(SAG)* 
18.57 N/A N/A 
 siRNA 1 18.66 N/A N/A 
 siRNA 2 18.56 N/A N/A 
 siRNA 5 18.42 N/A N/A 
 siRNA 7 18.8 N/A N/A 
 Brd4 18.45 N/A N/A 
 Brd4 control 18.53 N/A N/A 
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Overexpression of BRPF1 in Light2 Cells Does Not Affect Gli1 Expression 
RT-qPCR was also used to investigate the effects of BRPF1 
overexpression in Light2 cells (Figure 6). In the 20,000-cells/well plate (Figure 
6A), transfection led to a 200,000-fold increase in BRPF1 expression with 
positive SAG induction. Transfection efficiency was lower in the 40,000-
cells/well plate (Figure 6B) with only a 30,000- to 90,000-fold increase. In 
addition, oddly enough, fold increase was higher in cells incubated with DMSO 
than those incubated with SAG. Transfection efficiency was lowest in the 
80,000-cells/well plate (Figure 6C) with a maximum fold increase of ~45,000 in 
BRPF1 (SAG) cells. In all samples, there was no real change seen in Gli1 
expression (Figure 7). Ct values were again normalized to Gapdh, and GFP 
(SAG) was used as the control (Tables 5, 6, and 7). 
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Figure 6: BRPF1 overexpression in Light2 cells. A. 20,000-cells/well plate. B. 40,000-
cells/well plate. C. 80,000-cells/well plate. All data was normalized to Gapdh, and GFP 
(SAG) was used as the control. Error bars indicate the SD of duplicate technical 
repeats. 
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Figure 7: Gli1 expression is unaffected by BRPF1 overexpression in Light2 cells. A. 
20,000-cells/well plate. B. 40,000-cells/well plate. C. 80,000-cells/well plate. All data 
was normalized to Gapdh, and GFP (SAG) was used as the control. Error bars indicate 
the SD of duplicate technical repeats. 
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Table 5: RT-qPCR analysis of BRPF1 overexpression in Light2 cells (20,000-
cells/well plate). Gli1 and BRPF1 expression were both normalized to Gapdh. GFP 
(SAG) is marked with an “*” to indicate that it was set as the control. 
 
Gene Sample Ct (Threshold 
cycle) 
Normalization Standard 
deviation 
Gli1 GFP (DMSO) 34.87 0.10452 0.01395 
 GFP (SAG)* 31.44 1 0.15693 
 BRPF1 (DMSO) 34.83 0.09803 0.02293 
 BRPF1 (SAG) 31.58 1.08459 0.02085 
BRPF1 GFP (DMSO) 33.02 0.78977 0.23666 
 GFP (SAG)* 32.5 1 0.07744 
 BRPF1 (DMSO) 15.64 122566.4 9095.08 
 BRPF1 (SAG) 15.1 205804.4 3825.314 
Gapdh GFP (DMSO) 18.21 N/A N/A 
 GFP (SAG)* 18.03 N/A N/A 
 BRPF1 (DMSO) 18.07 N/A N/A 
 BRPF1 (SAG) 18.29 N/A N/A 
 
 
 
Table 6: RT-qPCR analysis of BRPF1 overexpression in Light2 cells (40,000-
cells/well plate). Gli1 and BRPF1 expression were both normalized to Gapdh. GFP 
(SAG) is marked with an “*” to indicate that it was set as the control. 
 
Gene Sample Ct (Threshold 
cycle) 
Normalization Standard 
deviation 
Gli1 GFP (DMSO) 34.86 0.04713 0.00151 
 GFP (SAG)* 30.23 1 0.04492 
 BRPF1 (DMSO) 34.77 0.04652 0.01545 
 BRPF1 (SAG) 30.16 1.13913 0.15173 
BRPF1 GFP (DMSO) 33.14 0.49843 0.04402 
 GFP (SAG)* 31.91 1 0.14015 
 BRPF1 (DMSO) 16.62 43330.34 1016.402 
 BRPF1 (SAG) 17.07 31875.2 2281.17 
Gapdh GFP (DMSO) 18.39 N/A N/A 
 GFP (SAG)* 18.17 N/A N/A 
 BRPF1 (DMSO) 18.28 N/A N/A 
 BRPF1 (SAG) 18.28 N/A N/A 
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Table 7: RT-qPCR analysis of BRPF1 overexpression in Light2 cells (80,000-
cells/well plate). Gli1 and BRPF1 expression were both normalized to Gapdh. GFP 
(SAG) is marked with an “*” to indicate that it was set as the control. 
 
Gene Sample Ct (Threshold 
cycle) 
Normalization Standard 
deviation 
Gli1 GFP (DMSO) 34.19 0.02283 0.00271 
 GFP (SAG)* 28.84 1 0.1242 
 BRPF1 (DMSO) 34.45 0.01913 0.00133 
 BRPF1 (SAG) 29.17 0.78199 0.09323 
BRPF1 GFP (DMSO) 32.93 0.84962 0.29393 
 GFP (SAG)* 32.8 1 0.30997 
 BRPF1 (DMSO) 17.62 34531.66 4049.065 
 BRPF1 (SAG) 17.34 43941.08 5822.75 
Gapdh GFP (DMSO) 17.88 N/A N/A 
 GFP (SAG)* 17.99 N/A N/A 
 BRPF1 (DMSO) 17.89 N/A N/A 
 BRPF1 (SAG) 17.96 N/A N/A 
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DISCUSSION !
We initially thought that BRPF1 functioned as a negative regulator of 
SHH-MB since a number of large potential loss-of-function mutations also led to 
activation of the SHH pathway20,63. However, our preliminary findings may 
actually point to its role as a positive regulator. Recent studies verify this 
hypothesis at least partially stating that BRPF1 functions as both a positive and 
negative regulator of gene expression depending on the context52,53. That said, it 
might also be possible that these large-scale mutations act via a dominant 
negative mechanism similar to p53. Thus, before we can draw any final 
conclusions, current experiments need to be repeated and verified, making 
necessary modifications, and further studies need to be performed investigating 
BRPF1’s role in the specific context of the SHH pathway and developing 
cerebellum. 
 
BRPF1 as a Positive Regulator of GLI Activity? 
Our preliminary findings seem to support BRPF1’s role as a positive 
regulator in SHH-MB. Brpf1 levels were higher in tumor samples (see Figure 3), 
and knockdown of Brpf1 in Light2 cells correlated with an overall decrease in 
Gli1 expression (see Figure 5). As positive regulators activate transcription, 
these findings suggest that BRPF1 may in fact play an oncogenic role in SHH-
GLI signaling. 
! ! !
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Still, these findings are extremely preliminary, and other studies have 
shown that BRPF1 can activate or repress transcription depending on cellular 
and developmental contexts52,53,54. Moreover, these studies argue that BRPF1’s 
repressive role is specific to the brain52,53. Thus, in order to understand BRPF1’s 
role in the cerebellum, knockdown studies should really be carried out in the 
brain itself. SHH Light2 cells are useful for looking at SHH activity, but they do 
not compare with real-life conditions in the brain, especially during its 
development. In addition, the finding that there are higher levels of Brpf1 in 
tumor cerebellum alone does not necessarily make it a positive regulator. For 
years, p53 or “the guardian of the genome” was considered an oncogene 
because of its accumulation in cancer cells65. It was later discovered that 
mutated p53 exerts a dominant negative effect over the wild-type protein, 
preventing it from binding to various target genes and suppressing its ability to 
induce cell cycle arrest66. In summary, we do not have enough information to 
characterize BRPF1 as either a positive or negative regulator of GLI activity, and 
it will likely oscillate between classification as an oncogene and as a tumor 
suppressor until new discoveries are made. 
 
Troubleshooting and Improving Current Experiments 
The first aim of our study was to compare basal levels of Brpf1 
expression in normal versus tumor cerebellum. While we found that Brpf1 was 
! ! !
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higher in SHH-MB samples (see Figure 3), our study was limited in that we only 
looked at Ptch+/- tumors. As mentioned previously, there are different subtypes 
of SHH-MB based on age group/genetic background11,20, and each subtype 
likely has a different basal composition. Adding to this, our immunoblot failed to 
detect any BRPF1 proteins in both normal and tumor cerebellum (see Figure 4). 
More than likely, this was due to a problem with the antibody; however, we 
cannot rule out that this particular subtype may not express BRPF1. Hence, a 
simple way to improve this experiment moving forward would be to add a 
positive control lysate, such as samples from cells made to overexpress the 
BRPF1 protein. 
The second aim of our study was two-pronged, the first being to 
characterize Brpf1 knockdown in SHH cell lines. We were excited to find that 
percent knockdown of Brpf1 roughly mirrored changes in Gli1 expression (see 
Figure 5); however, with knockdown efficiencies hanging around 30-40%, it was 
difficult to make any definitive statements. Most researchers consider >70% to 
be a “good” knockdown percentage and anything less to be an ineffective 
knockdown and poor transfection. Being that fellow researchers followed this 
same protocol (see Methods) and had good knockdown in Light2 cells, we 
doubt that there was an issue with how these cells were transfected and instead 
believe that there was an issue with the cells themselves. Cell cultures change 
over time, diverging in phenotype and growth characteristics compared to cells 
! ! !
32 
from earlier passages. Thus, we plan to repeat these experiments and see if 
siRNA delivery improves with a newly thawed batch of cells. 
The second prong of this aim was to characterize overexpression of 
BRPF1 in Light2 cells. Although no real change was seen in Gli1 expression (see 
Figure 7), we were able to successfully transfect and overexpress GFP-BRPF1 
plasmids in all cell samples (see Figure 6). Because transfection efficiency was 
best in the 20,000-cells/well plate, we plan on repeating this experiment to try 
and verify our findings. Also of note, the plasmid of interest held the human 
BRPF1 gene, not the mouse gene, which could possibly explain why Gli1 
expression was unaffected. Therefore, in future experiments, we might also 
consider using a mouse plasmid instead of the human plasmid. 
Overall, we were most concerned about the Ct values obtained for Gli1 
expression. Ideally, for SHH signaling to be considered active, Ct values should 
hang around 20-25. However, in our RT-qPCR analyses for knockdown and 
overexpression studies, Ct values fell between 30-37 (Tables 3-7). This is 
probably a technical error as other colleagues performed like experiments and 
collected appropriate Ct data. Still, before moving forward with any new 
experiments, we plan to make sure that these values are falling within the 
expected range. 
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Future Research 
   One in 1,000,000 cancer cells carries resistance to any single-agent 
therapeutic, and by the time a tumor is visible, it already contains around 
1,000,000,000 cells67. Therefore, it is a mathematical certainty that some cells 
will be resistant to a drug before it is even administered67. In this way, it was not 
surprising that those patients who initially responded to vismodegib later 
developed resistance and became refractory to treatment11,42,43. While targeted 
therapies are undoubtedly the future of cancer treatment, hitting these tumors 
from only one angle, with a single-agent therapeutic, seems to only guarantee 
resistance and ultimately relapse. Thus, one way to overcome this resistance 
may be the use of targeted therapy combinations. 
 Clinical trials for the use of vismodegib in SHH-MB are still ongoing; 
however, based on individual case studies and results from earlier trials, we can 
already predict that there will be an issue with resistance18,43. Thus, future 
studies should focus on a second line of drugs, using vismodegib in 
combination with another SHH inhibitor. This is in part what makes BRPF1’s 
discovery as a potential positive regulator so exciting. Negative regulators are 
considered undruggable because researchers have yet to discover how to 
restore tumor suppressor function68. As a positive regulator that acts 
downstream of SMO, BRPF1 represents a viable drug target that warrants 
further research.!  
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